AbSci, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on the stock and has a $8.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Debanjana Chatterjee’s rating is based on several promising aspects of AbSci’s ABS-101. The upcoming interim results from the Phase 1 trial are anticipated to demonstrate competitive pharmacology and safety, which could significantly boost confidence in AbSci’s design capabilities. If ABS-101 shows a strong safety profile and favorable pharmacokinetics, it could advance directly into more convenient subcutaneous dosing, enhancing its appeal to potential partners.
Moreover, the drug’s pharmacodynamics suggest it could achieve or surpass target engagement levels of existing treatments, and its low immunogenicity profile is another positive factor. The crowded TL1A monotherapy space means differentiation is key, and ABS-101’s unique combination of features could make it attractive to large pharmaceutical companies. Additionally, the potential for a TL1A-bispecific deal by early 2026 further supports the Buy rating, as it could lead to lucrative partnerships before the completion of IND enabling studies.